Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Zanamivir in Hospitalized Influenza
NCT01527110Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zanamivir in influenza, sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and 4 AE, SAE, Fatal AE, Number of Participants With Clinical Chemistry Parameters Outside Normal Range and 3 more. Started Jan 2012; status: completed.
02
Drugs
zanamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01527110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527110.